Dr. Akkaraju has been a director since July 2001. Since April 2001, Dr. Akkaraju has been a principal of the Life Sciences team in the Healthcare Group at JPMorgan Partners, LLC, formerly Chase Capital Partners, a global private equity company affiliated with J.P. Morgan Chase & Co. From October 1998 to April 2001, he was in the Business and Corporate Development group at Genentech, Inc., most recently as senior manager, where he was responsible for worldwide partnering activities including technology access deals, in-licensing of early and late-stage therapeutics, and out-licensing of Genentech development projects. In addition to his business development role, he also served for the last year as project team leader for one of Genentech's clinical development products. During this time, Dr. Akkaraju was also a founding member of BioStreet, an online marketplace for biotech opportunities. Prior to joining Genentech in 1998, Dr. Akkaraju was a graduate student at Stanford University. Dr. Akkaraju is a director of Seattle Genetics, Inc., a biotechnology company. Dr. Akkaraju received his undergraduate degrees in Biochemistry and Computer Science from Rice University and his M.D. and Ph.D. in Immunology from Stanford University.

Mr. Glick is a co-founder of our company and has been a director since February 2000. Mr. Glick has served as Executive Vice President and Chief Financial Officer of Theravance Inc, a biopharmaceutical company, since July 1998. From 1988 to October 1997, Mr. Glick held various positions at Genentech, Inc., including serving as Vice President of Finance from 1995 to October 1997. Mr. Glick is the chair of the Biotechnology Industry Organization's Tax and Finance Committee. Mr. Glick received his M.B.A. in Finance from the Kellogg School of Management at Northwestern University. Mr. Glick is also a Certified Public Accountant and a Chartered Accountant (Canada).

John McLaughlin is a co-founder of our company and has been our Chairman of the Board and a director since February 2000. Mr. McLaughlin has served as President and Chief Executive Officer of Corgentech, Inc., a publicly-traded biopharmaceutical company, since January 2000. From December 1997 to September 1999, Mr. McLaughlin was president of Tularik, Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr. McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including Executive Vice President, with responsibility for many commercial functions. Mr. McLaughlin served as a counsel to the United States House of Representatives committee responsible for drafting several of the FDA laws, including those governing orphan drugs, generic drug approvals, patent term extensions and export of unapproved drugs from the United States, and previously practiced law in Washington, D.C. Mr. McLaughlin received his J.D. from Catholic University and B.A. from the University of Notre Dame.

Dr. Patel is a co-founder of our company and has been a director since February 2000. From 1992 to December 2003, Dr. Patel served as the Director of the Retina Service at the University of Chicago, where he is an Associate Professor. His main area of research at the University of Chicago was focused on AMD. Dr. Patel served as the Residency Program Director at the University of Chicago from 1992 until July 2000. Dr. Patel received his M.D. from the University of Massachusetts Medical School and was an ophthalmology resident at the University of Chicago. Dr. Patel completed his fellowship training in retinal surgery at the Massachusetts Eye and Ear Infirmary, a teaching affiliate of Harvard Medical School.

Mr. Phillip M. Satow joined the Board of Directors in June 2004. From 1985 to 1998, Mr. Satow was Executive Vice President of Forest Laboratories, Inc. (NYSE: FRX), responsible for sales and marketing. In 1998, Mr. Satow was elected to the Board of Directors of Forest Laboratories and was appointed President of Forest Pharmaceuticals. Mr. Satow currently serves on the Board of Directors of Forest Laboratories and Crucell, Inc., a publicly-traded biotech company. Mr. Satow previously spent 14 years at Pfizer, Inc., in positions of increasing responsibility including Director of Marketing, Pfizer Laboratories, and Vice President, Pfizer Europe. Mr. Satow is also a Founder of The Jed Foundation, a public charity focused upon college mental health and suicide prevention. He was graduated from Columbia College and, after four years as a naval officer, received a Master of Arts degree in Economics from Georgetown University

Mr. Simon has been a director since July 2001. Since 1987, Mr. Simon has held various positions with Schroder Ventures in London, a global private equity group, serving as the Chief Executive Officer of the life sciences team until 1997, its Chairman from April 1997 to December 2001 and a Special Partner since January 2002. Mr. Simon has been Chairman of Leica Microsystems AG since 1998, Chairman of Zarlink Semiconductors since 1994 and a director of Gyros AB since September 2002. From 1988 to 1997, he was the Chairman of Shire Pharmaceuticals and from 1993 to 1996 also served as the Chairman of Chiroscience. Prior to joining Schroder Ventures, Mr. Simon was President of Technicon Corporation, a diagnostics manufacturer, and prior to that Group Executive and Vice President of ITT Europe. Mr. Simon started his career at Bell Laboratories in 1959 after graduating from the Institute of Technology in Munich, Germany and the Royal Institute of Technology in Stockholm, Sweden.

Michael J. Regan joined the Board of Directors in June 2004. Mr. Regan is a former Vice Chairman and the Chief Administrative Officer of KPMG LLP, a leading provider of audit and tax services. Over his 40 years with KPMG, Mr. Regan was involved in a wide range of business activities, was lead audit partner for many well-known Fortune 500 companies and was head of the New York Audit Practice. He is a graduate of Manhattan College and served four years as a naval officer. Mr. Regan is currently a member of the Board of Trustees of Manhattan College and a member and former chairman of the Board of Directors of the United Way of Bergen County, New Jersey.

Dr. Wicker has been a director since July 2001. Dr. Wicker is currently co-head of Life Sciences and Healthcare Infrastructure of JPMorgan Partners, LLC. Since December 1996, Dr. Wicker has been a partner with JPMorgan Partners. Prior to joining JPMorgan Partners in 1993, Dr. Wicker was President of Adams Scientific, a medical diagnostics company, and held various positions with MBW Venture Partners, a venture capital firm. Dr. Wicker was also a Commonwealth Fund Medical Fellow for the National Institute of Health. He is currently a member of the NVCA Life Science Group Board and the Board of Trustees of the New York Academy of Medicine. Dr. Wicker is also a Director of V.I. Technologies, Inc., a biotechnology company. Dr. Wicker received a B.S. with honors from M.I.T, an M.D. from The Johns Hopkins University School of Medicine, and an M.B.A. from The Wharton School of the University of Pennsylvania.